Cardior Pharmaceuticals

Dear Cardiors, dear partners and friends of Cardior, I am writing to share some personal news and to express my heartfelt gratitude. After a successful and dynamic transition process following Cardior’s acquisition by Novo Nordisk, I will be stepping down as CEO of Cardior Pharmaceuticals. This journey has been incredible, and I am deeply thankful to all of you. First and foremost, to the talented Thomas Thum for his breakthrough science on non-coding RNAs; to our investors, who believed in us and helped us along the way; to all our Cardior partners for their unwavering support and partnership; to the Novo Nordisk team for believing in the potential of our innovation and the clear and transparent collaboration throughout the acquisition process. However, my biggest thanks go to every one of our 30 people team! Dear Cardiors, your confidence, enthusiasm and relentless work have been instrumental in our success, and I am very proud to have led such a wonderful team! Together as a team we have achieved incredible milestones and overcome numerous challenges. From a six-people biotech start-up on the grounds of Hannover Medical School to an over one billion EUR deal with a global pharma company like Novo Nordisk in just seven years! At breathtaking speed, we achieved one milestone after another. 80 M EUR raised in A and B financing rounds, preclinical development, successfully completed Phase 1b Study, Phase 2 Study going on in over 60 Clinical Centers in 8 countries around Europe, and the second Phase 2 Study soon to be started. The acquisition marks a new chapter for our lead compound, one that has the potential to bring breakthrough treatment to many heart patients around the world, and I am confident that our compound is in the best of hands. On a personal note, this transition is bittersweet. While I am excited about our success, I will miss working with such an amazing team. Your dedication and passion have been truly inspiring. As I move on to new adventures, I look forward to staying connected. This is not a goodbye, but a ‘see you later. Stay tuned to my LinkedIn Dr. Claudia Ulbrich. Thank you once again for your support and friendship. Here’s to new beginnings and continued success for all of us! Yours, Claudia Ulbrich

As the festive holiday season kicks-off, we feel it is the right time to share our warmest thanks for your support to Cardior over the past years. The last year was transformative with the acquisition of Cardior Pharmaceuticals by Novo Nordisk as announced in March of this year. Novo Nordisk has the expertise and resources to accelerate the late-stage development for CDR132L, which brings us a significant step closer to achieving our main goal: developing life-saving treatments for heart patients. We are grateful for all the hard work and dedication from the Cardior team which enabled this milestone, and we look forward to seeing #RNA-based therapies transforming the treatment landscape for patients living with #heartfailure.

Last night during WirtschaftsWoche’s #HMGWintercamp2024, our CEO and Co-Founder Dr. Claudia Ulbrich was celebrated as one of Germany’s 30 by 2030. This initiative highlights inspiring personalities who will drive innovation for Germany in the next 15 years and Claudia was recognized for her track record as a serial entrepreneur in biotech. Access the recording for 🌟🚀 WirtschaftsWoche Mutmacher - Deutschlands 30 bis 2030 🚀🌟 here: https://lnkd.in/e8rvj3Rd

Our CEO and Co-Founder, Dr. Claudia Ulbrich has been named one of “Deutschlands 30 bis 2030” by the German outlet WirtschaftsWoche, honoring innovators, pioneers, and creative minds who will shape Germany in the next years. Access the full success story on how Claudia and the Cardior team are driving innovation for biotech in Germany here: https://lnkd.in/eeFqmJVB The awards will be celebrated during the #HMGWinterCamp 2024 on December 11th, and Claudia is looking forward to discussing the latest trends and challenges for 2025 in Düsseldorf.

Our CSO/CMO and Founder Thomas Thum will attend the CVCT - Cardiovascular Clinical Trialists Forum in Washington DC, from 9-11 December. This forum is dedicated to bringing together and fostering exchange between key stakeholders and experts for cardiovascular health and related fields from all over the world. Make sure to contact Thomas if you are at CVCT next week! Learn more about the forum here: https://lnkd.in/eFwdTmA #cvct2024 #CVCT #globaltrials #clinicalresearch #clinicaltrials

We are proud to have been represented at the Falling Walls Foundation Science Summit 2024, where our CEO & Co-Founder, Dr. Claudia Ulbrich moderated the panel session “Biomedical Innovation Ecosystems: Recipes for Success.” The session brought together leading experts to discuss how collaboration, cutting-edge research, and strategic investment are driving breakthroughs in healthcare and improving patient outcomes. Thank you to the Falling Walls Foundation for hosting such an inspiring event to advance the future of biomedical innovation.

We’re pleased to announce that Dr. Claudia Ulbrich, will be attending the 34th Frankfurt European Banking Congress, hosted by Germany’s leading banks in Frankfurt am Main. This year’s theme, “Out of the Comfort Zone: Europe and the New World Order,” promises insightful discussions with influential leaders from the political, business, financial, and academic sectors on Europe’s evolving role in the global landscape. We’re eager to explore how these insights connect to the biotech sector and impact financial markets. If you’re attending, be sure to connect with Claudia during the conference! #EuropeanBankingCongress #Biotech #Finance

Our CEO and Co-Founder, Dr. Claudia Ulbrich, is joining a panel discussion at the HQ Trust Investors Forum 2024 during Euro Finance Week. Claudia will speak alongside financial experts from investment firms and academia and share her experience from Cardior’s recent acquisition by Novo Nordisk, providing insights into our journey from early innovation to strategic growth. Learn more about the conference here: https://lnkd.in/ed2Hwrsh #EuroFinanceWeek #HQTrustForum #BiotechInnovation

We are happy to share that Cardior Pharmaceuticals’ CEO and Co-Founder Dr. Claudia Ulbrich is going to attend Jefferies 2024 London Healthcare Conference held in London on November 19-21.  The conference provides a comprehensive overview of the global healthcare sector and highlights upcoming trends. If you are attending as well, make sure to get in touch! 

Later this week, CEO and Co-Founder Dr. Claudia Ulbrich Ulbrich and CSO/CMO and Founder Dr. Thomas Thum will participate in the 2024 Falling Walls Science Summit, where thought leaders in science, business, and policy unite to explore innovative solutions and break down barriers in science. November 8: Claudia will join the Executive Table discussion on Charting a Path towards Precision Heart Health. This exclusive session brings together global experts to address the urgent challenges in heart health, exploring transformative research, AI applications, and personalized medicine. November 9: Both Claudia and Thomas will participate in the Executive Table discussion on Engineering Biology. This conversation will delve into how harnessing biological systems can reshape healthcare by accelerating vaccine development, diagnostics, and biologics production for a more accessible and robust global health landscape. Claudia Ulbrich will moderate the Roundtable Discussion on Biomedical Innovation Ecosystems: Recipes for Success. This session will explore the critical components of a thriving biomedicine innovation ecosystem, from funding and regulatory support to tech advancements and knowledge-sharing culture. #FallingWalls #ScienceSummit #Innovation